demands that price, impacting access to essentials like insulin," he said, adding that countries reliant on low prices might face drug access issues, and the United States might see delays in new drug launches
Primary-progressive multiple sclerosis
Most of these symptoms improve over time as the body adapts, but they can be significant enough to cause discontinuation in some patients
This minimizes even the slowest degradation pathways
"We expected there might be some stigma around using a GLP-1," Erin Standen, assistant professor of psychological sciences at Rice University, said in a statement
Retatrutide is an investigational peptide that has completed phase II clinical trials, with phase III trials underway or in planning